Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exact Sciences Cor (EXAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 5,473,836
  • Shares Outstanding, K 119,100
  • Annual Sales, $ 99,380 K
  • Annual Income, $ -167,210 K
  • 36-Month Beta 0.75
  • Price/Sales 53.93
  • Price/Cash Flow 0.00
  • Price/Book 9.91

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.64 +15.94%
on 08/25/17
46.15 -0.41%
on 09/22/17
+5.44 (+13.43%)
since 08/22/17
3-Month
33.86 +35.74%
on 06/28/17
46.15 -0.41%
on 09/22/17
+11.25 (+32.41%)
since 06/22/17
52-Week
13.05 +252.18%
on 01/03/17
46.15 -0.41%
on 09/22/17
+24.51 (+114.27%)
since 09/22/16

Most Recent Stories

More News
Today's Research Reports on Trending Tickers: Exact Sciences and Inovio Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / September 22, 2017 / U.S. markets retreated from record highs a day after the Federal Reserve announced that it would begin unwinding its $4.5 trillion balance sheet in October...

EXAS : 45.96 (+2.13%)
INO : 6.15 (-2.23%)
Smart Medical Device Could Save Millions of Lives

Stroke and heart diseases cost the U.S. nearly $1 billion every day in medical costs and lost productivity, so when a small-cap biotech company finally starts releasing validation news for a medical device...

EXAS : 45.96 (+2.13%)
CLBS : 3.80 (+0.26%)
SHPG : 155.09 (-0.17%)
REGN : 432.72 (-0.17%)
Medical Research Stock Performance Review -- Exact Sciences, DexCom, and PAREXEL

If you want a Stock Review on EXAS, DXCM, or PRXL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. As access to health care expands around the world,...

PRXL : 87.99 (-0.01%)
EXAS : 45.96 (+2.13%)
DXCM : 69.99 (+0.71%)
Exact Sciences to participate in Baird Global Healthcare Conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Baird Global Healthcare Conference on Wednesday, Sept. 6.

EXAS : 45.96 (+2.13%)
Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)

Exact Sciences Corporation (EXAS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

EXAS : 45.96 (+2.13%)
Today's Research Reports on Trending Tickers: Ionis Pharmaceuticals Inc. and Exact Sciences Corporation

NEW YORK, NY / ACCESSWIRE / August 23, 2017 / U.S. markets surged Tuesday, with the Dow Jones Industrial Average posting its best daily gain since April, on renewed hopes for tax reform. The Dow Jones...

EXAS : 45.96 (+2.13%)
IONS : 51.32 (-0.98%)
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%

Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth....

AGEN : 4.10 (unch)
EXAS : 45.96 (+2.13%)
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $57.6 million and completed approximately 135,000 Cologuard tests during the quarter ended June 30, 2017. Second-quarter...

EXAS : 45.96 (+2.13%)
Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

EXAS : 45.96 (+2.13%)
IMGN : 6.55 (+0.77%)
NVLS : 2.40 (+2.13%)
RHHBY : 32.0200 (-0.06%)
Why Exact Sciences (EXAS) Might Surprise This Earnings Season

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

EXAS : 45.96 (+2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in...

See More

Support & Resistance

2nd Resistance Point 47.11
1st Resistance Point 46.53
Last Price 45.96
1st Support Level 45.00
2nd Support Level 44.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.